Lung Cancer Screening

Lee, Elizabeth; Kazerooni, Ella A.

doi:10.1055/s-0042-1757885

Cited by 25 publications

(20 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Suitability of a screening program depends on the selection of a target risk population that would benefit from screening, the accuracy of the screening test, its frequency and duration, as well as the economic burden and adverse effects [ 24 ]. Radiation exposure is one of the major harms associated to LCS.…”

Section: The Problem Of Radiation Exposure In Lung Cancer Screeningmentioning

confidence: 99%

Radiation Exposure to Low-Dose Computed Tomography for Lung Cancer Screening: Should We Be Concerned?

Pozzessere

Garnier

2023

Tomography

View full text Add to dashboard Cite

Lung cancer screening (LCS) programs through low-dose Computed Tomography (LDCT) are being implemented in several countries worldwide. Radiation exposure of healthy individuals due to prolonged CT screening rounds and, eventually, the additional examinations required in case of suspicious findings may represent a concern, thus eventually reducing the participation in an LCS program. Therefore, the present review aims to assess the potential radiation risk from LDCT in this setting, providing estimates of cumulative dose and radiation-related risk in LCS in order to improve awareness for an informed and complete attendance to the program. After summarizing the results of the international trials on LCS to introduce the benefits coming from the implementation of a dedicated program, the screening-related and participant-related factors determining the radiation risk will be introduced and their burden assessed. Finally, future directions for a personalized screening program as well as technical improvements to reduce the delivered dose will be presented.

show abstract

Section: The Problem Of Radiation Exposure In Lung Cancer Screeningmentioning

confidence: 99%

Radiation Exposure to Low-Dose Computed Tomography for Lung Cancer Screening: Should We Be Concerned?

Pozzessere

Garnier

2023

Tomography

View full text Add to dashboard Cite

show abstract

“…The National Lung Screening Trial demonstrated a significant reduction in mortality with screening based on age and history of tobacco exposure [24]. LDCT is currently recommended by the United States Preventative Services Task Force for patients between the ages of 50 and 80, with at least a 20 pack-year smoking history and who are currently smoking or have stopped within the last 15 years [25]. The use of LDCT has been shown to detect lung cancers at earlier stages once screening programs are implemented [26].…”

Section: Workupmentioning

confidence: 99%

“…the last 15 years [25]. The use of LDCT has been shown to detect lung cancers at earlier stages once screening programs are implemented [26].…”

Section: Workupmentioning

confidence: 99%

The Role of Sublobar Resection for the Surgical Treatment of Non-Small Cell Lung Cancer

et al. 2023

View full text Add to dashboard Cite

Lung cancer is the most common cancer killer in the world. The standard of care for surgical treatment of non-small cell lung cancer has been lobectomy. Recent studies have identified that sublobar resection has non-inferior survival rates compared to lobectomy, however. Sublobar resection may increase the number of patients who can tolerate surgery and reduce postoperative pulmonary decline. Sublobar resection appears to have equivalent results to surgery in patients with small, peripheral tumors and no lymph node disease. As the utilization of segmentectomy increases, there may be some centers that perform this operation more than other centers. Care must be taken to ensure that all patients have access to this modality. Future investigations should focus on examining the outcomes from segmentectomy as it is applied more widely. When employed on a broad scale, morbidity and survival rates should be monitored. As segmentectomy is performed more frequently, patients may experience improved postoperative quality of life while maintaining the same oncologic benefit.

show abstract

“…Lung cancer is one of the common malignant cancers worldwide (Lee and Kazerooni, 2022). There are about 236,740 new cases of lung cancer and about 130,180 deaths from this disease in the United States (Siegel et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer

et al. 2023

View full text Add to dashboard Cite

Lung cancer is one of the common malignant cancers worldwide. Immune checkpoint inhibitor (ICI) therapy has improved survival of lung cancer patients. However, ICI therapy leads to adaptive immune resistance and displays resistance to PD-1/PD-L1 blockade in lung cancer, leading to less immune response of lung cancer patients. Tumor microenvironment (TME) is an integral tumor microenvironment, which is involved in immunotherapy resistance. Nanomedicine has been used to enhance the immunotherapy in lung cancer. In this review article, we described the association between TME and immunotherapy in lung cancer. We also highlighted the importance of TME in immunotherapy in lung cancer. Moreover, we discussed how nanoparticles are involved in regulation of TME to improve the efficacy of immunotherapy, including Nanomedicine SGT-53, AZD1080, Nanomodulator NRF2, Cisplatin nanoparticles, Au@PG, DPAICP@ME, SPIO NP@M-P, NBTXR3 nanoparticles, ARAC nanoparticles, Nano-DOX, MS NPs, Nab-paclitaxel, GNPs-hPD-L1 siRNA. Furthermore, we concluded that targeting TME by nanoparticles could be helpful to overcome resistance to PD-1/PD-L1 blockade in lung cancer.

show abstract

Lung Cancer Screening

Cited by 25 publications

References 67 publications

Radiation Exposure to Low-Dose Computed Tomography for Lung Cancer Screening: Should We Be Concerned?

Radiation Exposure to Low-Dose Computed Tomography for Lung Cancer Screening: Should We Be Concerned?

The Role of Sublobar Resection for the Surgical Treatment of Non-Small Cell Lung Cancer

Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer

Contact Info

Product

Resources

About